During the past decade, The Center for Diabetes and Endocrine Care conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 12 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Center for Diabetes and Endocrine Care" #1 sponsor was "Corcept Therapeutics" with 4 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Gan and Lee Pharmaceuticals, USA" with 3 trials sponsored and "Cortendo AB" with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Center for Diabetes and Endocrine Care" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "The Center for Diabetes and Endocrine Care" are "Diabetes Mellitus, Type 2" (6 trials), "Diabetes Mellitus, Type 1" (5 trials), "Type 2 Diabetes Mellitus" (5 trials), "Cushing's Syndrome" (4 trials) and "Diabetes" (2 trials). Many other conditions were trialed in "The Center for Diabetes and Endocrine Care" in a lesser frequency.

Most popular intervention types in "The Center for Diabetes and Endocrine Care" are "Drug" (31 trials), "Biological" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Insulin Degludec" (4 trials), "Gan & Lee Insulin Glargine Injection" (2 trials), "Insulin Glargine" (2 trials) and "Insulin Lispro" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Center for Diabetes and Endocrine Care" are 35 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "The Center for Diabetes and Endocrine Care". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in The Center for Diabetes and Endocrine Care, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Center for Diabetes and Endocrine Care, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".